Skip to main content Skip to main navigation menu Skip to site footer

PD-L1 overexpression in prostate cancer: a potential targeted therapy

  • Gede Andi Aditya ,
  • Yurisal Akhmad Dany ,
  • Raden Danarto ,
  • Indrawarman Soeroharjo ,
  • Ahmad Zulfan Hendri ,


Abstract

Link of Video Abstract: https://youtu.be/AUncKUx_dlQ

Background: Prostate cancer frequently presents with a non-specific clinical appearance, similar to benign prostatic hyperplasia (BPH). In many countries, early detection and treatment of prostate cancer are associated with lower mortality rates. Several prostate cancer biomarkers have been studied, one of which is programmed death ligand-1 (PD-L1), currently used as a therapeutic method. This study aimed to examine the expression of PD-L1 in prostate cancer and BPH.

Methods: This was a cross-sectional retrospective study involving subjects diagnosed with prostate cancer by histopathological examination. The expression of PD-L1 from 30 prostate tissues was analyzed using qRT-PCR. Data were then analyzed using the ANOVA test and continued with the Post Hoc test. P < 0.05 was considered significant.

Results: From a total of 30 prostate tissues that were examined histopathologically, ten samples were BPH (33.3%), ten samples were non-metastatic prostate cancer (non-MPCa) (33.3%), ten samples were metastatic prostate cancer (MPCa) (33.3%). The data analysis showed significant differences in PD-L1 expression between groups (p=0.000). The Post Hoc test showed significant differences between the non-MPCa group and BPH (p=0.003; 95% CI 36.1-142.8) and the MPCa group with BPH (p=0.000; 95% CI 50.9-127.3).

Conclusion: PD-L1 was overexpressed in the prostate cancer group, both in non-metastatic Pca and metastatic Pca. As a result, using PD-L1 inhibitors in the early stages of the disease may improve survival and prognosis.

Keywords: PD-L1 Prostate cancer

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492.
  2. World Health Organization. Globocan Indonesia 2020. 2021. Available at: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
  3. Isaacsson Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol. 2018;11(5):475-486. https://doi.org/10.1080/17512433.2018.1464388.
  4. Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, Majores M, Stein J, Uhl B, Müller S, Ellinger J, Stephan C, Jung K, Brossart P, Kristiansen G. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clin Cancer Res. 2016 Apr 15;22(8):1969-77. https://doi.org/10.1158/1078-0432.ccr-15-2042
  5. Zou W, Chen L. Inhibitory B7-family molecules in the tumor microenvironment. Nat Rev Immunol 2008;8:467–77. https://doi.org/10.1038/nri2326
  6. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027–34. https://doi.org/10.1084/jem.192.7.1027
  7. Chen DS, Irving BA, Hodi FS. Molecular Pathways: Next Generation Immunotherapy-Inhibiting Programmed Death-Ligand1 and Programmed Death-1. Clin. Cancer Res. 2012;18:6680-7. https://doi.org/10.1158/1078-0432.CCR-12-1362
  8. Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine. 2017 ;96(18):e6369. https://doi.org/10.1097/MD.0000000000006369.
  9. Sharma M, Yang Z, Miyamoto H. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer. Medicine (Baltimore). 2019;98(38):e17257. https://doi.org/10.1097/MD.0000000000017257.
  10. Fankhauser CD, Schüffler PJ, Gillessen S, et al. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget. 2017;9:10284–93. https://doi.org/10.18632/oncotarget.22888.
  11. Mujal A, Leslie SW. Gleason Score. StaatPearl. 2021. (Available at: https://www.ncbi.nlm.nih.gov/books/NBK553178/).
  12. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int. 2002;89(6). p538-42. https://doi.org/10.1046/j.1464-410x.2002.02669.x.
  13. Swanson GP, Trevathan S, Hammonds KAP, Speights VO, Hermans MR. Gleason Score Evolution and the Effect on Prostate Cancer Outcomes. Am J Clin Pathol. 2021 Apr 26;155(5):711-717. https://doi.org/10.1093/ajcp/aqaa130.
  14. Haffner MC, Guner G, Taheri D, et al. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. Am J Pathol 2018;188:1478–85. https://doi.org/10.1016/j.ajpath.2018.02.014.
  15. Xu Y, Song G, Xie S, Jiang W, Chen X, Chu M, Hu X, Wang ZW. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther. 2021 Jun 2;29(6):1958-1969. https://doi.org/10.1016/j.ymthe.2021.04.029.
  16. Baas W, Gershburg S, Dynda D, et al. Immune characterization of the programmed death receptor pathway in high-risk prostate cancer. Clin Genitourin Cancer 2017;15:577–81. https://doi.org/10.1016/j.clgc.2017.04.002.
  17. Ness N, Anderson S, Rakaee M, et al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget 2017;8:26789–801. https://doi.org/10.18632/oncotarget.15817.
  18. Ebelt K, Babaryka G, Frankenberger B, et al. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer 2009;45:1664–72. https://doi.org/10.1016/j.ejca.2009.02.015.
  19. He J, Yi M, Tan L, Huang J, Huang L. The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer. World J Surg Oncol. 2021 Jul 16;19(1):215. https://doi.org/10.1186/s12957-021-02325-z.
  20. Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res. 2016; 22(8): 1969-1977. https://doi.org/10.1158/1078-0432.CCR-15-2042.
  21. Petitprez F, Fossati N, Vano Y, et al. PD-L1 expression and CD8+ T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer. Eur Urol Focus 2019;5:192–6. https://doi.org/10.1016/j.euf.2017.05.01.

How to Cite

Aditya, G. A., Dany, Y. A., Danarto, R. ., Soeroharjo, I., & Hendri, A. Z. (2023). PD-L1 overexpression in prostate cancer: a potential targeted therapy. Bali Medical Journal, 12(2), 2303–2306. https://doi.org/10.15562/bmj.v12i2.4506
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
3

Total
2

Share

Search Panel

Gede Andi Aditya
Google Scholar
Pubmed
BMJ Journal

Yurisal Akhmad Dany
Google Scholar
Pubmed
BMJ Journal

Raden Danarto
Google Scholar
Pubmed
BMJ Journal

Indrawarman Soeroharjo
Google Scholar
Pubmed
BMJ Journal

Ahmad Zulfan Hendri
Google Scholar
Pubmed
BMJ Journal